REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has ...

– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...

RNA interference (RNAi) technology has gradually become a cutting-edge technology for treating diseases such as genetic disorders and cancer due to its huge potential in gene expression regulation.

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) therapeutics across several disease areas. The collaboration and license option ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

The FDA has granted Fast Track designation to BW-20805, an investigational small interfering RNA therapy for hereditary angioedema.

-- Financing led by LongRiver Investments with participation by new and existing global investment funds -- Rona will use proceeds to progress leading metabolic siRNA pipeline programs into global ...

Delivering cutting-edge peer-reviewed research on using nucleic acids and related compounds to alter gene expression for therapeutic purposes. Sarah Allen, from the University of Massachusetts Chan ...

An RNA interference (RNAi) molecule that selectively targets the KRAS G12V mutation could represent a key advance in the treatment of cancer associated with this oncogenic variant. Researchers at the ...